Global Non-melanoma Skin Cancer Market Will Grow at 27% CAGR to 2018 Says a Research Report at

Share Article

Global Non-melanoma Skin Cancer Market 2014-2018 is a market research report at that profiles key players in the Global Non-melanoma Skin Cancer Market like Elekta AB, F. Hoffmann-la Roche Ltd., iCAD Inc., Meda AB, Valeant Pharmaceuticals Inc. and Varian Medical Systems Inc.

Past News Releases


A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells. For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. Thicker hypertrophic lesions should be treated first with cryosurgery, gentle curettage, or even primed with applications of tretinoin cream or short courses of topical diclofenac sodium. The combination is chosen according to the size of the tumor and risk of recurrence.

Complete Report on Global Non-melanoma Skin Cancer Market 2014-2018 is spread across 119 pages and provides 42 List of Exhibits. Read the report at

Analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93% over the period 2013-2018. According to the report, the Global Non-melanoma Skin Cancer market is driven by several factors, of which the increasing prevalence of non-melanoma skin cancer resulting from factors such as increased exposure to UV rays, ozone layer depletion, and genetic mutation is one of the major drivers.

This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments: Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy.

The report recognizes the following companies as the key players in Global Non-melanoma Skin Cancer Market: Elekta AB, F. Hoffmann-la Roche Ltd., iCAD Inc., Meda AB, Valeant Pharmaceuticals Inc., Varian Medical Systems Inc., Aqua Pharmaceuticals LLC, Almirall SA, Biofrontera AG, Boehringer Ingelheim GmbH, Bristol Myers Squibb Co., Cannabis Science Inc., Cellceutix Corp., Eli Lilly and Co., Galderma SA, GENEXTRA SpA, IRX Therapeutics Inc., LEO Pharma A/S, Merck & Co. Inc., Moberg Pharma AB,Mylan Pharmaceutical Inc, Novartis International AG, Oncothyreon Inc., Sun Pharma Industries Ltd.

Purchase a copy of the report at Get 20% Discount on this report till May 22, 2015 at

Further, the report states that one of the major challenges faced by the market is the availability of alternative treatments such as surgery and non-invasive treatments. Surgery is the most preferred option for the treatment of BCC and SCC as its success rate is 99 percent. These alternative treatments limit the consumption of drugs.

About Us: is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website